-
Posted by
Two Blokes Jun 5 -
Filed in
Stock
-
16 views
23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company's former chief executive pushed a bankruptcy court to reopen its sale process.
